Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

ge for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    BioMS Medical Corp.
    (A Development Stage Corporation)
    Consolidated Balance Sheet
    December 31, 2008 and 2007
    -------------------------------------------------------------------------

    (expressed in thousands of Canadian dollars)

                                                             2008       2007
                                                                $          $

'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... ... ... The 2015 Market Research Report on the Global Propanol Industry ... market with a focus on the Chinese situation. Major companies included in the propanol ... Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report provides ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015   Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... supply industries, today reported financial results for the second ... half of 2015, we remain on track to achieve ... and Chief Executive Officer of the Company. "Since our ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... QUEBEC CITY, April 22 /PRNewswire-FirstCall/ - AEterna Zentaris ... a global biopharmaceutical company focused on endocrine therapy ... 1 results for its orally-active tubulin and topoisomerase ... solid tumors or lymphoma, which may potentially provide ...
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... and InnovationMOUNTAIN VIEW, Calif., April 22 The ... & Biotechnology group assesses a variety of critical ... cancer treatment. Physicians, nurses and patients provided ... home vs. office administration parameters, and barriers of ...
Cached Biology Technology:AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver 2AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... of California, San Diego have achieved the "Triple ... an artificial environment for stem cells that simultaneously ... for stem cell growth and differentiation. Building better ... realizing the promises of stem-cell-based regenerative medicine, including ...
... According to a popular hypothesis, grasses such as maize, ... as a result of a steep drop in atmospheric ... 23 million years ago. A new study overturns that ... of these and other C4 grasses emerged millions of ...
... With the help of babies and more than 5,000 ... accurate, noninvasive method to determine estrogen levels in infants. ... will allow researchers to learn more about the association ... reproductive development as well as the development of sex-specific ...
Cached Biology News:Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 2Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 3Bioengineers provide adult stem cells with simultaneous chemical, electrical and mechanical cues 4Study rewrites the evolutionary history of C4 grasses 2Infant estrogen levels tracked through diaper research 2Infant estrogen levels tracked through diaper research 3
... is a recombinant protein that has been shown ... the preparation of cDNA by reverse transcription, in ... synthesis. RNA Safe Inhibitor tightly binds RNases in ... of eukaryotic RNases such as RNase A, RNase ...
...
... RNase Inhibitor (Ribonuclease inhibitor) ... enzyme used to inhibit RNase ... DNase or endonuclease activity. , ... degradation of RNA template ...
...
Biology Products: